Literature DB >> 24022680

Impact of different vehicles for laser-assisted drug permeation via skin: full-surface versus fractional ablation.

Woan-Ruoh Lee, Shing-Chuan Shen, Ibrahim A Aljuffali, Yi-Ching Li, Jia-You Fang.   

Abstract

PURPOSE: This study aimed to assess impact of different vehicles for laser-assisted skin drug delivery. We also tried to uncover the mechanisms by which different vehicles affect laser-aided skin permeation.
METHODS: Full-surface ablative (conventional) and fractional lasers were used to irradiate nude mouse skin. Imiquimod and 5-aminolevulinic acid (ALA) were used as lipophilic and hydrophilic permeants. Vehicles employed included water with 40% polyethylene glycol 400 (PEG 400), propylene glycol (PG), and ethanol. Lipid nanoparticles were also utilized as carriers.
RESULTS: In vitro permeation profiles showed improvement in imiquimod flux with conventional laser (2.5 J/cm2) producing a 12-, 9-, and 5-fold increase when loading imiquimod in 40% PEG400, PG, and ethanol, respectively, as compared with intact skin. Nanoparticulate delivery by laser produced a 6-fold enhancement in permeation. Fractional laser produced less enhancement of imiquimod delivery than conventional laser. Laser exposure increased follicular imiquimod accumulation from 0.80 to 5.81 μg/cm2. ALA permeation from aqueous buffer, PEG 400, and PG with conventional laser treatment was 641-, 445-, and 104-fold superior to passive control. In vivo skin deposition of topically applied ALA examined by confocal microscopy indicated the same trend as the in vitro experiment, with aqueous buffer showing the greatest proporphyllin IX signaling. Diffusion of cosolvent molecules into ablated skin and drug partitioning from vehicle to skin are two predominant factors controlling laser-assisted delivery. In contrast to conventional laser, lateral drug diffusion was anticipated for fractional laser.
CONCLUSIONS: Our results suggest that different drug delivery vehicles substantially influence drug penetration enhanced by lasers.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24022680     DOI: 10.1007/s11095-013-1167-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  37 in total

1.  Ultrastructural evidence of stratum corneum permeabilization induced by photomechanical waves.

Authors:  Gopinathan K Menon; Nikiforos Kollias; Apostolos G Doukas
Journal:  J Invest Dermatol       Date:  2003-07       Impact factor: 8.551

2.  1064 nm-Nd:YAG lasers with different output modes enhancing transdermal delivery: physical and physiological mechanisms.

Authors:  Caihua Liu; Jie Zhang; Yuanlei Yue; Qingming Luo; Dan Zhu
Journal:  J Biomed Opt       Date:  2013-06       Impact factor: 3.170

3.  Facilitation of transcutaneous drug delivery and vaccine immunization by a safe laser technology.

Authors:  Xinyuan Chen; Dilip Shah; Garuna Kositratna; Dieter Manstein; Richard R Anderson; Mei X Wu
Journal:  J Control Release       Date:  2012-01-09       Impact factor: 9.776

4.  Erbium:YAG laser resurfacing increases skin permeability and the risk of excessive absorption of antibiotics and sunscreens: the influence of skin recovery on drug absorption.

Authors:  Woan-Ruoh Lee; Shing-Chuan Shen; Saleh A Al-Suwayeh; Yi-Ching Li; Jia-You Fang
Journal:  Toxicol Lett       Date:  2012-03-29       Impact factor: 4.372

5.  Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.

Authors:  Neil Swanson; William Abramovits; Brian Berman; James Kulp; Darrell S Rigel; Sharon Levy
Journal:  J Am Acad Dermatol       Date:  2010-02-04       Impact factor: 11.527

6.  Development of microemulsions to topically deliver 5-aminolevulinic acid in photodynamic therapy.

Authors:  Luciana Mattoso Pires de Campos Araújo; José Antônio Thomazine; Renata Fonseca Vianna Lopez
Journal:  Eur J Pharm Biopharm       Date:  2010-01-18       Impact factor: 5.571

Review 7.  Imiquimod: mode of action.

Authors:  M P Schön; M Schön
Journal:  Br J Dermatol       Date:  2007-12       Impact factor: 9.302

Review 8.  Photodynamic therapy of skin cancer: controlled drug delivery of 5-ALA and its esters.

Authors:  Renata Fonseca Vianna Lopez; Norbert Lange; Richard Guy; Maria Vitória Lopes Badra Bentley
Journal:  Adv Drug Deliv Rev       Date:  2004-01-13       Impact factor: 15.470

9.  Topical delivery of methotrexate via skin pretreated with physical enhancement techniques: low-fluence erbium:YAG laser and electroporation.

Authors:  Woan-Ruoh Lee; Shin-Chuan Shen; Chia-Lang Fang; Rou-Zi Zhuo; Jia-You Fang
Journal:  Lasers Surg Med       Date:  2008-09       Impact factor: 4.025

Review 10.  Lipid nanoparticles for improved topical application of drugs for skin diseases.

Authors:  Monika Schäfer-Korting; Wolfgang Mehnert; Hans-Christian Korting
Journal:  Adv Drug Deliv Rev       Date:  2007-05-03       Impact factor: 15.470

View more
  5 in total

1.  Is the Fractional Laser Still Effective in Assisting Cutaneous Macromolecule Delivery in Barrier-Deficient Skin? Psoriasis and Atopic Dermatitis as the Disease Models.

Authors:  Woan-Ruoh Lee; Shing-Chuan Shen; Calvin T Sung; Pei-Ying Liu; Jia-You Fang
Journal:  Pharm Res       Date:  2018-04-26       Impact factor: 4.200

2.  Fractional thermolysis by bipolar radiofrequency facilitates cutaneous delivery of peptide and siRNA with minor loss of barrier function.

Authors:  Woan-Ruoh Lee; Shing-Chuan Shen; Chi-Kuang Sun; Ibrahim A Aljuffali; Shih-Yun Suen; Yin-Ku Lin; Jhi-Joung Wang; Jia-You Fang
Journal:  Pharm Res       Date:  2014-11-13       Impact factor: 4.200

3.  Vehicle type affects filling of fractional laser-ablated channels imaged by optical coherence tomography.

Authors:  Uffe Høgh Olesen; Mette Mogensen; Merete Haedersdal
Journal:  Lasers Med Sci       Date:  2017-02-17       Impact factor: 3.161

4.  Hypertrophic Scar Outcomes in Fractional Laser Monotherapy Versus Fractional Laser-Assisted Topical Corticosteroid Delivery: A Randomized Clinical Trial.

Authors:  Woraphong Manuskiatti; Arisa Kaewkes; Chadakan Yan; Janice Natasha Ng; Joshua Zev Glahn; Rungsima Wanitphakdeedecha
Journal:  Acta Derm Venereol       Date:  2021-03-17       Impact factor: 3.875

Review 5.  Topical and Transdermal Drug Delivery: From Simple Potions to Smart Technologies.

Authors:  Heather A E Benson; Jeffrey E Grice; Yousuf Mohammed; Sarika Namjoshi; Michael S Roberts
Journal:  Curr Drug Deliv       Date:  2019       Impact factor: 2.565

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.